Elicio Therapeutics, Inc. announced its financial results for the year ended December 31, 2025, reporting a net loss of $39.5 million. The company provided updates on its Phase 2 AMPLIFY-7P trial, with an anticipated DFS analysis in 1H 2026 and a cash runway projected into Q3 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.